和黃醫藥(00013.HK):將於2024年歐洲血液協會(EHA)年會公佈索樂匹尼布 (sovleplenib) ESLIM-01 III期研究以及血液惡性腫瘤項目數據
格隆匯5月17日丨和黃醫藥(00013.HK)今日宣佈將於2024年6月13日至6月16日在西班牙馬德里及線上舉行的歐洲血液協會(“EHA”)年會上公佈索樂匹尼布ESLIM-01 III期研究的頂線及亞組結果,以及創新探索性血液惡性腫瘤療法HMPL-306 、HMPL-760及他澤司他(tazemetostat)的最新及更新後的臨牀數據。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.